Here's the article about the CPXX buyout. Note to
Post# of 72440
http://www.fiercebiotech.com/biotech/after-ho...0ifQ%3D%3D
So, 1.5 billion bucks for a drug with a MUCH smaller potential patient base than any of CTIX's drugs.
CTIX has 122.54 million shares outstanding. We're talking ten bucks a share valuation if one of our drugs was sold for that much -- and our drugs have a much larger potential patient base.